These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32342933)

  • 1. Appropriateness of metformin prescription for type 2 diabetes mellitus patients with chronic kidney disease (Stages 3-5).
    Ramachandran M; Loi B; Mat Ariff N; Ng OC; Zahari Sham SY; Thambiah SC; Samsudin IN
    Malays J Pathol; 2020 Apr; 42(1):71-76. PubMed ID: 32342933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal function markers and metformin eligibility.
    Tavares Bello C; Castro Fonseca R; Sousa Santos F; Sequeira Duarte J; Azinheira J; Vasconcelos C
    Minerva Endocrinol; 2018 Sep; 43(3):246-252. PubMed ID: 28565889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3-5: is it significant?
    Prabhu RA; Mareddy AS; Nagaraju SP; Rangaswamy D; Guddattu V
    Int Urol Nephrol; 2019 Jul; 51(7):1229-1230. PubMed ID: 30963454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.
    Penfornis A; Blicklé JF; Fiquet B; Quéré S; Dejager S
    Vasc Health Risk Manag; 2014; 10():341-52. PubMed ID: 24966684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine.
    Tuot DS; Lin F; Shlipak MG; Grubbs V; Hsu CY; Yee J; Shahinian V; Saran R; Saydah S; Williams DE; Powe NR;
    Diabetes Care; 2015 Nov; 38(11):2059-67. PubMed ID: 26307607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin in chronic kidney disease: time for a rethink.
    Heaf J
    Perit Dial Int; 2014 Jun; 34(4):353-7. PubMed ID: 24711640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin: time to review its role and safety in chronic kidney disease.
    Tanner C; Wang G; Liu N; Andrikopoulos S; Zajac JD; Ekinci EI
    Med J Aust; 2019 Jul; 211(1):37-42. PubMed ID: 31187887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication safety and chronic kidney disease in older adults prescribed metformin: a cross-sectional analysis.
    Huang DL; Abrass IB; Young BA
    BMC Nephrol; 2014 Jun; 15():86. PubMed ID: 24906409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of serum creatinine and kidney function among incident metformin users.
    Schorr M; Hemmelgarn BR; Tonelli M; Soo A; Manns BJ; Bresee LC;
    Can J Diabetes; 2013 Aug; 37(4):226-230. PubMed ID: 24070885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lactate levels and risk of lactic acidosis with metformin in diabetic kidney disease patients.
    Bipi PK; George J; Gomathy S; Gracious N; Kumar S; Mohandas MK
    Saudi J Kidney Dis Transpl; 2017; 28(6):1356-1361. PubMed ID: 29265047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin in patients with type 2 diabetes and kidney disease: a systematic review.
    Inzucchi SE; Lipska KJ; Mayo H; Bailey CJ; McGuire DK
    JAMA; 2014 Dec 24-31; 312(24):2668-75. PubMed ID: 25536258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs.
    Lamine F; Lalubin F; Pitteloud N; Burnier M; Zanchi A
    Swiss Med Wkly; 2016; 146():w14282. PubMed ID: 26922155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription of oral antidiabetic drugs in K/DIGO chronic kidney disease stage 3 and 4: a single centre report.
    Fabbian F; De Giorgi A; Monesi M; Tiseo R; Storari A; Mallozzi Menegatti A; Pala M; Tomasi F; Portaluppi F; Manfredini R
    Minerva Urol Nefrol; 2014 Mar; 66(1):69-75. PubMed ID: 24721942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A cross-sectional analysis of the National Health and Nutrition Examination Survey.
    Gor D; Gerber BS; Walton SM; Lee TA; Nutescu EA; Touchette DR
    J Diabetes; 2020 May; 12(5):385-395. PubMed ID: 31652390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study.
    Alvarez CA; Halm EA; Pugh MJV; McGuire DK; Hennessy S; Miller RT; Lingvay I; Vouri SM; Zullo AR; Yang H; Chansard M; Mortensen EM
    Endocrinol Diabetes Metab; 2021 Jan; 4(1):e00170. PubMed ID: 33532612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of lactic acidosis-related parameters upon and after metformin discontinuation in patients with diabetes and chronic kidney disease.
    Sipahi S; Solak Y; Acikgoz SB; Genc AB; Yildirim M; Yilmaz U; Nalbant A; Tamer A
    Int Urol Nephrol; 2016 Aug; 48(8):1305-1312. PubMed ID: 27102431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease.
    Marcum ZA; Forsberg CW; Moore KP; de Boer IH; Smith NL; Boyko EJ; Floyd JS
    J Gen Intern Med; 2018 Feb; 33(2):155-165. PubMed ID: 29181788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safe Use of Metformin in Adults With Type 2 Diabetes and Chronic Kidney Disease: Lower Dosages and Sick-Day Education Are Essential.
    MacCallum L; Senior PA
    Can J Diabetes; 2019 Feb; 43(1):76-80. PubMed ID: 30061044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystatin C measurement leads to lower metformin dosage in elderly type 2 diabetic patients.
    Šálek T; Adamíková A
    Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):298-302. PubMed ID: 30218617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4.
    Lalau JD; Kajbaf F; Bennis Y; Hurtel-Lemaire AS; Belpaire F; De Broe ME
    Diabetes Care; 2018 Mar; 41(3):547-553. PubMed ID: 29305402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.